Role of molecular biology in the management of pancreatic cancer.

Fiche publication

Date publication

juillet 2024

Journal

World journal of gastrointestinal oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry , Dr LAMBERT Aurélien

Tous les auteurs :
Boileve A, Smolenschi C, Lambert A, Boige V, Tarabay A, Valery M, Fuerea A, Pudlarz T, Conroy T, Hollebecque A, Ducreux M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39072173

Résumé

Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations. This review explores key molecular alterations in PDAC, while emphasizing differences between -mutated and -wild-type tumours. It assesses the practical application of precision medicine in clinical settings and outlines potential future directions with respect to PDAC. Actionable molecular targets are examined with the aim of enhancing our understanding of PDAC molecular biology. Insights from this analysis may contribute to a more refined and personalized approach to pancreatic cancer treatment, ultimately improving patient outcomes.